Avita Medical Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Avita Medical Inc 's ROA in the third quarter of 2026?
Avita Medical Inc recorded a cumulative net loss of $-36 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -49.97%.

However, within the Healthcare sector 667 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4199, from total ROA ranking in the second quarter of 2026 at 4898.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-24.59 %	-17.82 %	-25.9 %	-11.08 %	-34.96 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-36	-43	-45	-49	-49
Return On Assets (TTM)	-49.97 %	-56.62 %	-57.62 %	-58.41 %	-55.4 %
RCEL's Total Ranking	# 4199	# 4898	# 4245	# 4309	# 4390
Total Assets (TTM) in million	47	48	52	143	62
Seq. Total Assets Change	-2.06 %	-7.31 %	-63.96 %	130.46 %	6.74 %
Seq. Net Income Change	-	-	-	-	-

RCEL's 5 Years Annual ROA >> Back to RCEL Management Effectiveness >> Compare RCEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 158
Sector	# 668
Overall	# 4117

Return On Assets Statistics
High	Average	Low
-19.51 %	-54.47 %	-128.47 %
(Sep 30 2021)		(Jun 30 2020)

Financial Statements
Avita Medical Inc 's Assets	$ 47 million	RCEL's Balance sheet
Avita Medical Inc 's Income	$ -6 million	Quarterly RCEL's Income Statement
RCEL's Income by Division		See RCEL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	-11.08 %	35.15 %	-22.32 %	31.43 %	48.31 %
Total Assets in million	143	161	119	153	117
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-49	-62	-35	-27	-27
Annual Return On Assets	-33.98 %	-38.45 %	-29.73 %	-17.41 %	-22.81 %

RCEL's 5 Years Annual ROA >> Back to RCEL Management Effectiveness >> Compare RCEL ROA to its Competitors

More Return On Assets Ratios
RCEL's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RCEL's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RCEL's Competitors
Subscribers only: Roa for Avita Medical Inc 's Suppliers
Subscribers only: Return On Assets for RCEL's Customers

You may also want to know
RCEL's Roi	RCEL's Inventory Turnover Ratio	RCEL's Growth Rates	RCEL's Dividend Comparisons
	RCEL's Profitability Ratios	RCEL's Asset Turnover Ratio	RCEL's Dividend Growth
RCEL's Roe	RCEL's Valuation Ratios	RCEL's Financial Strength Ratios	RCEL's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-08T19:41:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.